Zevra Therapeutics, Inc. (ZVRA)
$10.39-8.22%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $614M
- Beta
- 0.98
- P/E (TTM)
- 10.82
- Short % float
- 13.01%
- Days to cover
- 7.2
- SI change
- +24.6%
- 1W
- -3.17%
- 1M
- -13.78%
- vs SPY 1W
- -3.03%
- vs SPY 1M
- -16.28%
Industry peers
FMP comparable companies · ranked by market cap
- NBIXSELLNeurocrine Biosciences, Inc.$14.6BRECOVERYQ 16$145.51-4.41%
- JAZZSELLJazz Pharmaceuticals plc$14.5BBEARQ 24$231.39-2.93%
- PRAXSELLPraxis Precision Medicines, Inc.$7.8BCRISISQ 11$280.14-3.20%
- ALKSSELLAlkermes plc$7.0BRECOVERYQ 6$41.65-1.32%
- XENESELLXenon Pharmaceuticals Inc.$3.5BCRISISQ 22$36.57-3.88%
- SUPNBUYSupernus Pharmaceuticals, Inc.$2.5BRECOVERYQ 26$42.83-1.87%
- GHRSSELLGH Research PLC$1.5BCRISISQ 14$21.52-5.84%
- ANROSELLAlto Neuroscience, Inc.$831MCRISISQ 15$23.69-8.53%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ZVRA?
- LOPJLB’s latest quantitative signal on Zevra Therapeutics, Inc. (ZVRA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ZVRA in?
- Zevra Therapeutics, Inc. (ZVRA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Zevra Therapeutics, Inc. (ZVRA) do?
- Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily…